Evidence map›Paper›PMID 38265347›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2024

Assessing the reaction to and efficacy of the Screener drug discovery and development board game as a pedagogical tool in postgraduate courses.

F Noël, G Xexéo, M A Martins, E J R Silva, A S Pupo, P J C Magalhães, R C P Lima-Júnior, K K L Gadelha, K Lima-Silva, J M Raimundo and 12 more

Abstract read
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

F NoëlPrograma de Pós-Graduação em Farmacologia e Química Medicinal, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.ORCID http://orcid.org/0000-0001-6813-1347
G XexéoLaboratório de Ludologia, Engenharia e Simulação, Programa de Engenharia de Sistemas e Computação, COPPE, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.ORCID http://orcid.org/0000-0003-3975-9076
M A MartinsLaboratório de Inflamação, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.ORCID http://orcid.org/0000-0002-4708-5705
E J R SilvaDepartamento de Biofísica e Farmacologia, Instituto de Biociências de Botucatu, Universidade Estadual Paulista, Botucatu, SP, Brasil.ORCID http://orcid.org/0000-0002-9330-8658
A S PupoDepartamento de Biofísica e Farmacologia, Instituto de Biociências de Botucatu, Universidade Estadual Paulista, Botucatu, SP, Brasil.ORCID http://orcid.org/0000-0001-6627-3448
P J C MagalhãesPrograma de Pós-Graduação em Farmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil.ORCID http://orcid.org/0000-0002-9073-5750
R C P Lima-JúniorPrograma de Pós-Graduação em Farmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil.ORCID http://orcid.org/0000-0002-7033-655X
K K L GadelhaPrograma de Pós-Graduação em Farmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil.ORCID http://orcid.org/0000-0001-8758-6662
K Lima-SilvaPrograma de Pós-Graduação em Farmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil.ORCID http://orcid.org/0000-0001-5764-7946
J M RaimundoGrupo de Pesquisa em Farmacologia de Produtos Bioativos, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Macaé, RJ, Brasil.ORCID http://orcid.org/0000-0001-9152-4931
P C GhediniDepartamento de Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brasil.ORCID http://orcid.org/0000-0003-2104-4064
M E Crespo-LopezLaboratório de Farmacologia Molecular, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil.ORCID http://orcid.org/0000-0002-1335-6853
G P ArrifanoLaboratório de Farmacologia Molecular, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil.ORCID http://orcid.org/0000-0003-2817-3539
J FerreiraPrograma de Pós-graduação em Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, Brasil.ORCID http://orcid.org/0000-0002-9562-0602
R D PredigerPrograma de Pós-graduação em Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, Brasil.ORCID http://orcid.org/0000-0002-7547-6463
G C G MilitãoDepartamento de Fisiologia e Farmacologia, Centro de Biociências, Universidade Federal de Pernambuco, Recife, PE, Brasil.ORCID http://orcid.org/0000-0002-7865-5002
R B OliveiraPrograma de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.ORCID http://orcid.org/0000-0001-5884-2567
A W HollaisPrograma de Pós-Graduação em Ciências Fisiológicas, Universidade Federal do Espírito Santo, Vitória, ES, Brasil.ORCID http://orcid.org/0000-0002-2991-8646
L C M RodriguesPrograma de Pós-Graduação em Ciências Fisiológicas, Universidade Federal do Espírito Santo, Vitória, ES, Brasil.ORCID http://orcid.org/0000-0002-6004-7981
D T CarvalhoFaculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas, Alfenas, MG, Brasil.ORCID http://orcid.org/0000-0002-6362-2822
S K P CostaDepartamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0002-2574-4490
D T O MartinsPrograma de Pós-Graduação em Ciências da Saúde, Laboratório de Farmacologia, Faculdade de Medicina, Universidade Federal de Mato Grosso, Cuiabá, MT, Brasil.ORCID http://orcid.org/0000-0001-7695-9312

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Screener, a board game supplemented with online resources, was introduced and distributed by the Brazilian Society of Pharmacology and Experimental Therapeutics to postgraduate programs as an instructional tool for the process of drug discovery and development (DDD). In this study, we provided a comprehensive analysis of five critical aspects for evaluating the quality of educational games, namely: 1) description of the intervention; 2) underlying pedagogical theory; 3) identification of local educational gaps; 4) impact on diverse stakeholders; and 5) elucidation of iterative quality enhancement processes. We also present qualitative and quantitative assessments of the effectiveness of this game in 11 postgraduate courses. We employed the MEEGA+ online survey, comprising thirty-three close-ended unipolar items with 5-point Likert-type response scales, to assess student perceptions of the quality and utility of Screener. Based on 115 responses, the results indicated a highly positive outlook among students. In addition, we performed a preliminary evaluation of learning outcomes in two courses involving 28 students. Pre- and post-quizzes were applied, each consisting of 20 True/False questions directly aligned with the game's content. The analysis revealed significant improvement in students' performance following engagement with the game, with scores rising from 8.4 to 13.3 (P<0.0001, paired t-test) and 9.7 to 12.7 (P<0.0001, paired t-test). These findings underscore the utility of Screener as an enjoyable and effective tool for facilitating a positive learning experience in the DDD process. Notably, the game can also reduce the educational disparities across different regions of our continental country.

Indexed as

Drug DiscoveryLearningBrazilDietary SupplementsEducational StatusHumans

Identifiers

PMID38265347
PMCPMC10802222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.